Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Treasury Shares: 2019-2025

  • Dr Reddys Laboratories' Treasury Shares rose 125.00% to $27.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $27.0 million, marking a year-over-year increase of 125.00%. This contributed to the annual value of $27.0 million for FY2025, which is 125.00% up from last year.
  • Dr Reddys Laboratories' Treasury Shares amounted to $27.0 million in Q1 2025, which was up 125.00% from $12.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Treasury Shares high stood at $27.0 million for Q1 2021, and its period low was $12.0 million during Q1 2024.
  • Moreover, its 3-year median value for Treasury Shares was $15.0 million (2023), whereas its average is $18.0 million.
  • As far as peak fluctuations go, Dr Reddys Laboratories' Treasury Shares fell by 28.57% in 2023, and later spiked by 125.00% in 2025.
  • Quarterly analysis of 5 years shows Dr Reddys Laboratories' Treasury Shares stood at $27.0 million in 2021, then declined by 22.22% to $21.0 million in 2022, then fell by 28.57% to $15.0 million in 2023, then decreased by 20.00% to $12.0 million in 2024, then soared by 125.00% to $27.0 million in 2025.
  • Its Treasury Shares stands at $27.0 million for Q1 2025, versus $12.0 million for Q1 2024 and $15.0 million for Q1 2023.